Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Inevitable Outcome: Diabetes Safety Model Expands To Weight Loss…And Beyond?

May 23 2012

Related Content

A Tale of Two Drugs: Meridia and Avandia, and the Issues that Separated Them

Nov 01 2010

Patient Advocacy 3.0: Outreach Stretches to First Stages of Regulatory Development

Apr 16 2012

Weighing the Regulatory Climate: Qnexa and the New Approval Model

Sep 01 2010

Just a Minute: The Final Step in Advisory Committee Process

Mar 01 2011

FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately

Apr 15 2009

CV Risk Assessment For All Obesity Drugs Seems Inevitable Pre-Approval Requirement

Mar 30 2012

Regulatory Innovation: A Dialogue (Part II)

Mar 15 2012

Related Companies

University of Colorado

GSK plc

Vivus, Inc.

Arena Pharmaceuticals, Inc.

Abbott

Cedars-Sinai Medical Center

AstraZeneca PLC

Tufts University

Novo Nordisk A/S

Sanofi

US Department of Health and Human Services

George Washington University

Additional Topics

Regulation Post Market Regulation & Studies BioPharmaceutical

More from Archive

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window